Last Updated: 2026

InventisBio

Summary

Summary

InventisBio Co., Ltd., a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company's drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer, etc. indications. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications. The company has a collaboration agreement with Betta Pharma to out-license D-0316's right in China to Betta Pharma; and to co-develop it in China. InventisBio Co., Ltd. was founded in 2013 and is headquartered in Pudong, China.

History

InventisBio was founded in 2015 in Boston, Massachusetts. We have grown to be a dynamic and innovative leader in the life sciences industry, with a strong focus on leveraging cutting-edge technology to develop products and solutions that will be beneficial to both researchers and patients. We are dedicated to fostering innovation in the field of biomedical research and providing our customers with high-quality resources and services.

Mission

Our mission is to provide innovative products that drive life science research and patient health outcomes. We are dedicated to delivering timely, accurate and reliable products and services that will improve the quality of life. Furthermore, we are committed to empowering people to achieve their full potential and positively impacting our community by creating jobs and opportunities for growth.

Vision

Our vision is to revolutionize biomedical research and patient care by leveraging data-driven insights and cutting-edge technology. We are committed to delivering tailored solutions and technologies to our customers that will revolutionize the way healthcare is delivered.

References

https://in.investing.com/equities/inventisbio

https://finance.yahoo.com/quote/688382.SS/profile?p=688382.SS

https://www.crunchbase.com/organization/inventisbio-2

https://www.inventisbio.com

Leadership team

Dr. Yaolin Wang (CEO & Chairman)

Mr. Xing Dai (Director and Deputy Gen. Mang.)

Products / Services

Biopharma, Biotechnology, Pharmaceutical

Number of Employees

0 - 50